Gluten in “gluten-free” manufactured foods in Australia: a cross-sectional study
Authors: Emma P Halmos, Dean Clarke, Catherine Pizzey and Jason A Tye-Din
Published online: 12 November 2018
More frequent gluten testing would reduce the risk for people with coeliac disease
Patients with coeliac disease must strictly adhere to a gluten-free diet. Two potential sources of inadvertent gluten exposure are meals provided when dining out and manufactured “gluten-free” foods. A recent study1 found that 9% of gluten-free food samples from Melbourne food businesses failed to meet the national standard of “no detectable gluten”2. As no data on gluten levels in manufactured “gluten-free” foods in Australia have been published, we measured the gluten content of a broad sample of these foods.
The 300 foods labelled “gluten-free” most commonly purchased in Australia were identified in August 2017 in a consumer activity database (The Nielsen Company, Homescan Online: https://homescan.acnielsen.com.au). Two hundred and fifty-six of the identified food items could be obtained from 16 large retail supermarkets, ten discount or independent supermarkets, and one specialty health food supermarket. The sequence in which we analysed the samples was recorded to allow detection of contamination of samples during preparation and analysis by a preceding positive sample. Foods were homogenised on the day of purchase and analysed at the National Measurement Institute in Melbourne. All samples were assayed in duplicate with the RIDASCREEN R5 gliadin kit (R-Biopharm), which has a limit of quantification for gluten of 5 mg/kg (parts per million, ppm) and a detection limit of 1 ppm gluten. To validate our findings, positive samples were also analysed with the AgraQuant G12 gluten kit (Romer Labs). If gluten was detected in a sample, a fresh sample of the food was purchased and analysed. The manufacturers of products containing detectable gluten were notified. The study was approved by the Melbourne Health Human Research Ethics Committee (reference, 2016/070).
The agreement between results of the R5 and G12 assays was good. Seven samples (2.7%) from six manufacturers contained detectable gluten at levels of up to 49 ppm. Two of these samples were from the same manufacturer and contained the same two ingredients (not named to protect identity of the manufacturer). One of the seven items had already been recalled by its manufacturer; follow-up batches of five of the other six items also contained quantifiable levels of gluten (5–21 ppm) (Box).
The integrity of manufactured foods labelled “gluten-free” is imperative for people with coeliac disease, but in Australia only one formal analysis (of imported foods) has been published.3 We found that 2.7% of foods labelled “gluten-free” were not compliant with the national standard of no detectable gluten; two contained gluten at levels exceeding the less strict Codex Alimentarius CODEX (Europe) and Food and Drug Administration (United States) thresholds for “gluten-free” labelling (20 ppm). While the gluten content per standard food serve was generally low, the 3 mg gluten per serve of “gluten-free” pasta could be harmful, especially if consumed frequently.4 Repeat batches of five of seven contaminated foods also contained gluten, indicating that the initial results did not reflect isolated episodes of contamination. As three of the seven items were produced in dedicated gluten-free factories, gluten contamination of ingredients supplied by outside sources should be examined.
Our findings indicate that inadvertent gluten ingestion is more likely when dining out1 than when consuming manufactured “gluten-free foods”. Nevertheless, more frequent gluten testing, feasible for many companies,5 would reduce the risk for people with coeliac disease.
Box – Gluten content of “gluten-free” manufactured foods
|
Food item |
Assay |
||||||||||||||
|
RIDASCREEN R5 (gliadin) |
AgraQuant G12 (gluten) |
||||||||||||||
|
Gluten (ppm): initial test |
Gluten in standard serving (mg)* |
Gluten (ppm): follow-up test |
Gluten (ppm) |
||||||||||||
|
|
|||||||||||||||
|
Fruit/muesli bar |
< 5.0 |
— |
< 1.0 |
6.4 |
|||||||||||
|
Noodles |
5.0 |
0.38 (single serving, dry; 75 g) |
14 |
10 |
|||||||||||
|
Cracker |
6.0 |
0.09 (2.5 crackers; 15 g) |
13 |
6.5 |
|||||||||||
|
Fruit/muesli bar |
10 |
0.40 (one bar; 40 g) |
21 |
9.0 |
|||||||||||
|
Cracker |
19 |
0.48 (one cracker; 25 g) |
5.0 |
14 |
|||||||||||
|
Rice snacks |
24 |
0.48 (single serving; 20 g) |
NA |
21 |
|||||||||||
|
Dry pasta |
49 |
3.1 (0.5 cup, dry; 62.5 g) |
8.0 |
51 |
|||||||||||
|
|
|||||||||||||||
|
NA = not applicable (product recalled by manufacturer); ppm = parts per million. * Standard serving size based on nutrition information panel for product. |
|||||||||||||||
Competing interests
Jason Tye-Din is a co-inventor on patents pertaining to applications of gluten peptides in therapeutics, diagnostics, and non-toxic gluten; he is a shareholder in Nexpep and a consultant to ImmusanT (USA).
Acknowledgements
Emma Halmos was funded by a research grant from Coeliac Australia. We thank the Nielsen Company for their data on the most commonly purchased foods; and Martina Koeberl, Jasmit Khangurha and Rasika Wijerathne (National Measurement Institute) for conducting the food analyses.
References
- Halmos EP, Di Bella CA, Webster R, et al. Gluten in “gluten-free” food from food outlets in Melbourne: a cross-sectional study. Med J Aust 2018; 209: 42-43.
- Food Standards Australia New Zealand. Standard 1.2.7. Nutrition, health and related claims. Nov 2017. https://www.legislation.gov.au/Details/F2017C01048 (viewed Apr 2018).
- Forbes GM, Dods K. Gluten content of imported gluten-free foods: national and international implications. Med J Aust 2016; 205: 316.
- Catassi C, Fabiani E, Iacono G, et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr 2007; 85: 160-166.
- Zurzolo GA, Peters RL, Koplin JJ, et al. The practice and perception of precautionary allergen labelling by the Australasian food manufacturing industry. Clin Exp Allergy 2017; 47: 961-968.
Linked content
-
MJA Letter: Gluten in “gluten‐free” manufactured foods in Australia: a cross‐sectional study
Australian Pathways for Specialist Pain Management and Early Palliative Care for People With Pancreatic Cancer: Developed Using a Community Consensus Approach
Jennifer Philip, Melanie R. Lovell, Kylee Bellingham, Gail Garvey, Gregory B. Crawford, Nicole M. Rankin, Kara Burns, Isabel Young, Vivienne Milch, Dorothy Keefe, Katrina Anderson, James Lawson, Meinir Krishnasamy
Cause‐specific mortality among Queensland people with cirrhosis, by cirrhosis aetiology and decompensation status, 2007–22: a retrospective cohort study
Vikas Bhasker, Jessica R Fong, Paul J Clark, Gunter F Hartel, Richard Skoien, James O’Beirne, Elizabeth E Powell, Patricia C Valery
Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: summary of recommendations
Jacob George, Nicole L Allard, Stuart K Roberts, Leon A Adams, Jane Davies, Behzad Hajarizadeh, Jennifer H MacLachlan, Suzanne E Mahady, Rosalie Altus, Catherine Brown, David C Fry, Belinda Greenwood‐Smith, Natali Smud, Patricia C Valery, Nafisa Yussf, Kate Broun, Denise Campbell, Karen Canfell, Chelsea Carle Harrison, Victoria Freeman, Paul Grogan, Catherine Holliday, Suzanne Hughes, Anna Kelly, Cathelijne Kemenade, Claire Latumahina, Amanda McAtamney, Megan Varlow, Joachim Worthington, Susan Yuill, Eleonora Feletto
Assessment of metabolic dysfunction‐associated fatty liver disease in primary care: a consensus statement summary
Leon A Adams, William W Kemp, Kate R Muller, Elizabeth E Powell, Stuart K Roberts, Luis Calzadilla Bertot, Stephanie Best, Gary Deed, Jon D Emery, Samantha L Hocking, Graham R Jones, John S Lubel, Sinead Sheils, Stephen M Twigg, Gerald F Watts, Jacob George
Treatment outcomes for people with hepatitis C referred to tertiary care in Victoria, 2021–22: a retrospective observational study
Elly Layton, Nicole Matthews, Brendan Quinn, Nasra Higgins, Gabrielle Lindeman, Mielle Abbott, Jennifer MacLachlan, Elizabeth Birbilis, Margaret E Hellard, Joseph Doyle, Benjamin C Cowie, Mark Stoové
Participation in the National Bowel Cancer Screening Program by people with severe mental illness, Australia, 2006–2019: a national data linkage study
Oyedeji Ayonrinde, Sara Mohamed, Jenna Nensi